---
document_datetime: 2023-09-21 17:35:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/kentera-epar-procedural-steps-taken-authorisation_en.pdf
document_name: kentera-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3818562
conversion_datetime: 2025-12-23 00:54:18.832967
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1 Submission of the dossier

The  applicant  Schein  Pharmaceuticals  UK  Ltd  submitted  on  6  December  2002  an  application  for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for  Oxybutynin Nicobrand, in accordance with the centralised procedure falling within the scope of Part  B  of  the  Annex  to  Council  Regulation  No  (EEC)  2309/93  of  22  July  1993,  as  amended. On  9  September  2003  the  EMEA  was  informed  of  a  name  change  of  the  applicant  from  Schein Pharmaceutical UK Ltd to Nicobrand Limited.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur: Dr. Pieter Neels

## Scientific Advice:

The applicant did not seek scientific advice from the CPMP.

## Licensing status:

Oxybutynin Nicobrand has been given a Marketing Authorisation in the USA on 03/03/2003. A new application is pending in Canada.

## 2 Steps taken for the assessment of the product

- The procedure started on 24 February 2003.
- The Rapporteur's first Assessment Report was circulated to all CPMP members on 9 May 2003. The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 6 May 2003.
- During the meeting on 26 June 2003, the CPMP agreed on the consolidated List of Questions to be sent to the applicant.
- The  summary  report  of  the  inspection  carried  out  at  the  manufacturing  site  of  the  finished product Watson Laboratories, Inc , Salt  Lake  City,  Utah,  USA, between 29-31 July 2003 was issued on 17 October 2003
- The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 9 September 2003.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CPMP members on  24 October 2003.
- Further to clarificatiom received from the Applicant on 11 November 2003, the Rapporteur and Co-rapporteur circulated an addendum to the Joint Assessment Report on 14 November 2003.
- During the meeting on 20 November 2003, the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Oxybutynin Nicobrand on 20 November 2003.
- The  European  Commission  requested  to  reconsider  this  application  according  to  a  different legal basis and subsequently to revise the initial Opinion of 20 November 2003.
- During  the  meeting  on  24-26  February  2004  the  CPMP,  in  the  light  of  the  overall  data  and justifications  submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  revised positive Opinion  for granting a Marketing  Authorisation  to  Oxybutynin  Nicobrand  on 26 February 2004.

Co-Rapporteur:

Prof. Cristina Sampaio